← back to search

Neal I. Lindeman

Cornell University · US
Area of research
Cancer Research · Pulmonary and Respiratory Medicine
Research interest
Research interests include Cancer Genomics and Diagnostics, Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, and Genetic factors in colorectal cancer.
h-index
71
citations
43,224
works
478
NIH funding
primary concept
email

Recent publications

Contemporary prognostic signatures and refined risk stratification of gliomas: An analysis of 4400 tumors
Neuro-Oncology 2024cited by 26position: middledoi
Recommendations for Tumor Mutational Burden Assay Validation and Reporting
Journal of Molecular Diagnostics 2024cited by 21position: middledoi
Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer
Nature Communications 2024cited by 7position: middledoi
A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE)
Molecular Cancer Therapeutics 2023cited by 44position: middledoi
Clinical Targeted Next-Generation Panel Sequencing Reveals <i>MYC</i> Amplification Is a Poor Prognostic Factor in Osteosarcoma
JCO Precision Oncology 2023cited by 30position: middledoi
Molecular Landscape and Contemporary Prognostic Signatures of Gliomas
medRxiv 2023cited by 1position: middledoi
Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer
Nature Medicine 2022cited by 64position: middledoi
Genomic analysis of early-stage lung cancer reveals a role for TP53 mutations in distant metastasis
Scientific Reports 2022cited by 20position: middledoi
Rare FGFR Oncogenic Alterations in Sequenced Pediatric Solid and Brain Tumors Suggest FGFR Is a Relevant Molecular Target in Childhood Cancer
JCO Precision Oncology 2022cited by 19position: middledoi
Corrigendum to: LTBK-01. Updates On The Phase Ii And Re-treatment Study Of AZD6244 (Selumetinib) For Children With Recurrent Or Refractory Pediatric Low Grade Glioma: A Pediatric Brain Tumor Consortium (PBTC) Study
Neuro-Oncology 2022cited by 11position: middledoi
Fatty acid synthesis is required for breast cancer brain metastasis
Nature Cancer 2021cited by 319position: middledoi
A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study
Neuro-Oncology 2021cited by 157position: middledoi
Tumor Mutational Burden and <i>PTEN</i> Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer
Clinical Cancer Research 2020cited by 184position: middledoi
Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial
The Lancet Oncology 2019cited by 496position: middledoi
Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer
Proceedings of the National Academy of Sciences 2019cited by 396position: middledoi
Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer
Journal of Clinical Oncology 2019cited by 215position: middledoi
LGG-02. A PHASE II PROSPECTIVE TRIAL OF SELUMETINIB IN CHILDREN WITH RECURRENT/PROGRESSIVE PEDIATRIC LOW-GRADE GLIOMA (PLGG) WITH A FOCUS UPON OPTIC PATHWAY/HYPOTHALAMIC TUMORS AND VISUAL ACUITY OUTCOMES: A PEDIATRIC BRAIN TUMOR CONSORTIUM (PBTC) STUDY, PBTC-029B
Neuro-Oncology 2019cited by 4position: middledoi
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors
Journal of Thoracic Oncology 2018cited by 630position: firstdoi
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors
Journal of Molecular Diagnostics 2018cited by 349position: firstdoi
Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma
Neuro-Oncology 2018cited by 133position: middledoi
LTBK-01. UPDATES ON THE PHASE II AND RE-TREATMENT STUDY OF AZD6244 (SELUMETINIB) FOR CHILDREN WITH RECURRENT OR REFRACTORY PEDIATRIC LOW GRADE GLIOMA: A PEDIATRIC BRAIN TUMOR CONSORTIUM (PBTC) STUDY
Neuro-Oncology 2018cited by 9position: middledoi
Comparison of Laboratory-Developed Tests and FDA-Approved Assays for <i>BRAF, EGFR,</i> and <i>KRAS</i> Testing
JAMA Oncology 2017cited by 36position: middledoi
A phase II prospective study of selumetinib in children with recurrent or refractory low-grade glioma (LGG): A Pediatric Brain Tumor Consortium (PBTC) study.
Journal of Clinical Oncology 2017cited by 16position: middledoi
Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer
Journal of Molecular Diagnostics 2016cited by 1,981position: middledoi
Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors
JAMA Oncology 2016cited by 204position: middledoi
Acute myeloid leukemia ontogeny is defined by distinct somatic mutations
Blood 2014cited by 973position: middledoi
Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine
Nature Medicine 2014cited by 569position: middledoi
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
Archives of Pathology & Laboratory Medicine 2013cited by 428position: firstdoi
MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction
Blood 2013cited by 410position: middledoi
Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions
Journal of Thoracic Oncology 2013cited by 358position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Azra H. Ligon · Harvard University4 papers (2017–2022)Lindsay Kilburn · Columbia University Irving Medical Center4 papers (2017–2022)Malcolm A. Smith · University of South Australia4 papers (2017–2022)Ibrahim Qaddoumi · Tennessee Oncology4 papers (2017–2022)Arzu Onar‐Thomas · Cancer Research And Biostatistics4 papers (2017–2022)Maryam Fouladi · University of Cincinnati4 papers (2017–2022)Ira J. Dunkel · National Cancer Institute4 papers (2017–2022)L. Austin Doyle · National Cancer Institute4 papers (2017–2022)Jason Fangusaro · Winship Cancer Institute4 papers (2017–2022)Shengjie Wu · St. Jude Children's Research Hospital4 papers (2017–2022)Marc Ladanyi · Center for Cancer Research3 papers (2013–2018)Philip T. Cagle · Weill Cornell Medicine3 papers (2013–2018)Girish Dhall · Children's of Alabama3 papers (2017–2022)Erik Thunnissen · Amsterdam UMC Location Vrije Universiteit Amsterdam3 papers (2013–2018)Ian F. Pollack · University of Pittsburgh3 papers (2017–2022)David J. Kwiatkowski · Harvard University3 papers (2013–2018)Sanja Đačić · Yale University3 papers (2013–2018)Anuradha Banerjee · Jawaharlal Nehru University3 papers (2017–2022)Tina Young Poussaint · Boston Children's Hospital3 papers (2018–2022)Patricia Baxter · Children's Cancer Center3 papers (2018–2022)